{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:04:03Z","timestamp":1792728243698,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital Linkou","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jgar.2024.03.014","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T18:10:30Z","timestamp":1711563030000},"page":"93-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Antimicrobial activity of eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in Taiwan: A clinical microbiological study"],"prefix":"10.1016","volume":"37","author":[{"given":"Ming-Han","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4591-0924","authenticated-orcid":false,"given":"Chyi-Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-6428","authenticated-orcid":false,"given":"Hsin-Ju","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Chun","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4324-7743","authenticated-orcid":false,"given":"Cheng-Hsun","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2024.03.014_bib0001","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3390\/molecules25061340","article-title":"Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jgar.2024.03.014_bib0002","article-title":"WHO priority pathogens list for R&D of new antibiotics WHO publishes list of bacteria for which new antibiotics are urgently needed","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.jgar.2024.03.014_bib0003","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2024.03.014_bib0004","article-title":"In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.03.014_bib0005","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.3390\/microorganisms10122506","article-title":"Stenotrophomonas maltophilia epidemiology, resistance characteristics, and clinical outcomes: understanding of the recent three years' trends","volume":"10","author":"Hafiz","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.jgar.2024.03.014_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciz089","article-title":"The Infectious Diseases Society of America's 10 \u00d7 \u201920 initiative (10 new systemic antibacterial agents US Food and Drug Administration approved by 2020): is 20 \u00d7 \u201920 a possibility?","volume":"69","author":"Talbot","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.03.014_bib0007","volume":"58","author":"Lee","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.03.014_bib0008","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jgar.2023.04.017","article-title":"In vitro activity of eravacycline and comparators against gram-negative and gram-positive bacterial isolates collected from patients globally between 2017 and 2020","volume":"33","author":"Hawser","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2024.03.014_bib0009","doi-asserted-by":"crossref","first-page":"e02206","DOI":"10.1128\/AAC.02206-17","article-title":"Evaluation of the in vitro activity of eravacycline against a broad spectrum of recent clinical anaerobic isolates","volume":"62","author":"Snydman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.03.014_bib0010","doi-asserted-by":"crossref","first-page":"ciad428","DOI":"10.1093\/cid\/ciad428","article-title":"Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant Gram-negative infections","author":"Tamma","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.03.014_bib0011","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.03.014_bib0012","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1089\/sur.2020.241","article-title":"Efficacy and tolerability of eravacycline in bacteremic patients with complicated intra-abdominal infection: a pooled analysis from the IGNITE1 and IGNITE4 studies","volume":"22","author":"Felice","year":"2021","journal-title":"Surg Infect"},{"key":"10.1016\/j.jgar.2024.03.014_bib0013","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jmii.2022.09.009","article-title":"In vitro susceptibility of common Enterobacterales to eravacycline in Taiwan","volume":"56","author":"Huang","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2024.03.014_bib0014","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2022"},{"key":"10.1016\/j.jgar.2024.03.014_bib0015","unstructured":"European committee on antimicrobial susceptibility testing; 2023. Breakpoint tables for interpretation of MICs and zone diameters. version 13.0. https:\/\/www.eucast.org\/eucast_news\/news_singleview?tx_ttnews%5Btt_news%5D=518&cHash=2509b0db92646dffba041406dcc9f20c."},{"key":"10.1016\/j.jgar.2024.03.014_bib0016","series-title":"Eravacycline\u2013injection products. FDA-identified interpretive criteria","year":"2022"},{"key":"10.1016\/j.jgar.2024.03.014_bib0017","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","article-title":"Correlation coefficients: appropriate use and interpretation","volume":"126","author":"Schober","year":"2018","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jgar.2024.03.014_bib0018","unstructured":"Centers for Disease Control, Taiwan. Taiwan Hospital infection control and antimicrobial Surveillance (THAS) System Report, 1st season. Taipei, Taiwan; 2020. https:\/\/www.cdc.gov.tw\/En\/Category\/Page\/J63NmsvevBg2u3I2qYBenw."},{"key":"10.1016\/j.jgar.2024.03.014_bib0019","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/AAC.00533-12","article-title":"Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2006 to 2010","volume":"56","author":"Tsai","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.03.014_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106353","volume":"58","author":"Tsai","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.03.014_bib0021","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2217\/fmb-2019-0135","article-title":"Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance","volume":"14","author":"Solomkin","year":"2019","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jgar.2024.03.014_bib0022","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12866-018-1349-7","article-title":"Eravacycline activity against clinical S. aureus isolates from China: in vitro activity, MLST profiles and heteroresistance","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.jgar.2024.03.014_bib0023","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02262-18","article-title":"Antimicrobial activity of omadacycline tested against clinical bacterial isolates from hospitals in Mainland China, Hong Kong, and Taiwan: results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016)","volume":"63","author":"Carvalhaes","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.03.014_bib0024","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.01310-21","article-title":"Novel tet (L) efflux pump variants conferring resistance to tigecycline and eravacycline in Staphylococcus spp","volume":"9","author":"Wang","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2024.03.014_bib0025","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00634-23","article-title":"Tigecycline resistance-associated mutations in the MepA efflux pump in Staphylococcus aureus","volume":"11","author":"Huang","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2024.03.014_bib0026","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/jac\/dkt255","article-title":"Lincosamide resistance mediated by lnu (C) (L phenotype) in a Streptococcus anginosus clinical isolate","volume":"68","author":"Gravey","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.03.014_bib0027","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.diagmicrobio.2006.08.001","article-title":"Tigecycline (GAR-936) activity against Streptococcus gallolyticus (bovis) and viridans group streptococci","volume":"57","author":"Moet","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.03.014_bib0028","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.anaerobe.2018.06.016","article-title":"In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species","volume":"52","author":"Goldstein","year":"2018","journal-title":"Anaerobe"},{"key":"10.1016\/j.jgar.2024.03.014_bib0029","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/cid\/ciaa912","article-title":"Emergence of clinical Clostridioides difficile isolates with decreased susceptibility to vancomycin","volume":"74","author":"Darkoh","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.03.014_bib0030","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/jac\/dkaa289","article-title":"In vitro activity of eravacycline against common ribotypes of Clostridioides difficile","volume":"75","author":"Bass\u00e8res","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.03.014_bib0031","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cmi.2017.07.012","article-title":"Susceptibilities of clinical Clostridium difficile isolates to antimicrobials: a systematic review and meta-analysis of studies since 1970","volume":"24","author":"Khanafer","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2024.03.014_bib0032","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3390\/antibiotics10101226","article-title":"Antimicrobial treatment strategies for Stenotrophomonas maltophilia: a focus on novel therapies","volume":"10","author":"Gibb","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2024.03.014_bib0033","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1128\/AAC.01774-09","article-title":"Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections","volume":"54","author":"Farrell","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.03.014_bib0034","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-\u03b2-lactamase inhibitor combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2024.03.014_bib0035","doi-asserted-by":"crossref","first-page":"ofaa071","DOI":"10.1093\/ofid\/ofaa071","article-title":"Early experience with eravacycline for complicated infections","volume":"7","author":"Alosaimy","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2024.03.014_bib0036","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40265-019-01067-3","article-title":"Eravacycline: a review in complicated intra-abdominal infections","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524000675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524000675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T03:27:47Z","timestamp":1718681267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716524000675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":36,"alternative-id":["S2213716524000675"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2024.03.014","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial activity of eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in Taiwan: A clinical microbiological study","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2024.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}